Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jun 10;13(12):2908.
doi: 10.3390/cancers13122908.

Predicting Colorectal Cancer Occurrence in IBD

Mehmet Yalchin  1   2 , Ann-Marie Baker  2 , Trevor A Graham  2 , Ailsa Hart  1
Affiliations
Review

Predicting Colorectal Cancer Occurrence in IBD

Mehmet Yalchin et al. Cancers (Basel). .

Abstract

Patients with colonic inflammatory bowel disease (IBD) are at an increased risk of developing colorectal cancer (CRC), and are therefore enrolled into a surveillance programme aimed at detecting dysplasia or early cancer. Current surveillance programmes are guided by clinical, endoscopic or histological predictors of colitis-associated CRC (CA-CRC). We have seen great progress in our understanding of these predictors of disease progression, and advances in endoscopic technique and management, along with improved medical care, has been mirrored by the falling incidence of CA-CRC over the last 50 years. However, more could be done to improve our molecular understanding of CA-CRC progression and enable better risk stratification for patients with IBD. This review summarises the known risk factors associated with CA-CRC and explores the molecular landscape that has the potential to complement and optimise the existing IBD surveillance programme.

Keywords: cancer risk; inflammatory bowel disease; molecular biomarkers; molecular risk factors; risk factors.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Demonstrates the known risk factors for predicting cancer risk in patients with IBD, and illustrates the potential novel directions for a molecular biomarker for disease progression. CIB—cumulative inflammatory burden, CRP—C-reactive protein.
See this image and copyright information in PMC

References

    1. Listrom C., Holt K. Inflammatory bowel disease. Emerg. Med. 2004;36:24–28.
    1. Kaser A., Zeissig S.B.R. Inflammatory bowel disease. Annu. Rev. Immunol. 2010;28:573–621. doi: 10.1146/annurev-immunol-030409-101225. - DOI - PMC - PubMed
    1. Alatab S., Sepanlou S.G., Ikuta K., Vahedi H., Bisignano C., Safiri S., Sadeghi A., Nixon M.R., Abdoli A., Abolhassani H., et al. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: A systematic analysis for the Global Burden of Disease Study. Lancet Gastroenterol. Hepatol. 2017;5:17–30. doi: 10.1016/S2468-1253(19)30333-4. - DOI - PMC - PubMed
    1. Ng S.C., Shi H.Y., Hamidi N., Underwood F.E., Tang W., Benchimol E.I., Panaccione R., Ghosh S., Wu J.C.Y., Chan F.K.L., et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies. Lancet. 2018;390:2769–2778. doi: 10.1016/S0140-6736(17)32448-0. - DOI - PubMed
    1. National Institute for Health and Clinical Excellence, Centre For Clinical Practice Scope, Ulcerative Colitis: The Management of Ulcerative Colitis. [(accessed on 12 May 2021)];2011 :1–10. Available online: https://www.nice.org.uk/guidance/cg166/documents/ulcerative-colitis-fina....

LinkOut - more resources